New Drug Application Filed for Sarepta’s Eteplirsen for Duchenne Muscular Dystrophy Treatment
News
Sarepta Therapeutics, Inc., a biopharmaceutical company focused on the development of innovative RNA-based therapeutics, recently announced that the U.S. Food and Drug Administration (FDA) has filed the New Drug Application (NDA) ... Read more